Drug Type Antibody drug conjugate (ADC) |
Synonyms BRY 812, BRY-812, BRY812 |
Target |
Action modulators, inhibitors |
Mechanism LIV-1 modulators(Zinc transporter ZIP6 modulators), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Endometrial Carcinoma | Phase 2 | - | 01 Dec 2025 | |
| Ovarian clear cell carcinoma | Phase 2 | - | 01 Dec 2025 | |
| Clear cell neoplasm of ovary | Phase 2 | China | 24 Oct 2025 | |
| Endometrial Carcinoma | Phase 2 | China | 24 Oct 2025 | |
| Female Genital Neoplasms | Phase 2 | China | 24 Oct 2025 | |
| Ovarian Cancer | Phase 2 | China | 24 Oct 2025 | |
| Ovarian Epithelial Carcinoma | Phase 2 | China | 24 Oct 2025 | |
| Advanced cancer | Phase 1 | China | 10 Oct 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 10 Oct 2023 | |
| Liver Cancer | Phase 1 | China | 10 Oct 2023 |
Phase 1 | Advanced Malignant Solid Neoplasm LIV-1 expression | 36 | tbkubbzfri(zglgedlhlb) = vevpnpwocy sjveyjwgrp (awwecsscxj ) View more | Positive | 30 May 2025 | ||
Phase 1 | 38 | pjezifxnmv(fussdvmoyz) = inlnqnkplu ndmgygjjad (hszppcjjlm ) | Positive | 30 May 2025 |






